Lifeboat Foundation

On pace with its once-a-month flight goal, Virgin Galactic is about to embark on its fifth commercial mission, and its final flight of 2023.

Galactic 5 is scheduled to lift off this Thursday (Nov. 2) and will carry three passengers on a brief trip to suborbital space. The trio will fly aboard Virgin Galactic’s SpaceShipTwo space plane, named VSS Unity, and experience several minutes of weightlessness while they perform a quick round of research experiments and gaze at the wonders of Earth from a vantage point few have reached.

Instead of flying directly to the moon, NASA and Blue Origin plan for the spacecraft to be refueled in transit — an innovation that could transform the way humans explore the cosmos.

Google has taken a significant step towards enhancing Chrome internet security by automatically upgrading insecure HTTP requests to HTTPS requests for 100% of users.

This feature is called HTTPS-Upgrades and will secure old links that utilize the http:// by automatically attempting to first connect to the URL over the encrypted https:// protocol.

A limited rollout of this feature in Google Chrome began in July, but as of October 16th, Google has now rolled it out to all users on the Stable channel.

https://informatech.co/3QEBncW by.

In a post on its leak site, prolific ransomware threat group LockBit claims that it breached Boeing, and said that it will start releasing sensitive data it purportedly stole from the company’s systems if ransom demands aren’t met by Nov. 2.

“A tremendous amount of sensitive data was exfiltrated and ready to be published if Boeing do (sic) not contact within deadline!” the LockBit post shared by cybersecurity analyst Dominic Alvieri read. “For now we will not send lists or samples to protect the company BUT we will not keep it like that until the deadline.”

Continue reading “Boeing Breached by Ransomware, LockBit Gang Claims” »

NASA hopes to address a glitch that garbled Voyager 1 data for several months in 2022.

They can produce twice as much solar fuel with the same input of concentrated solar radiation.

The current explosion of exciting commercial and open-source AI is likely to be followed, within a few years, by creepily superintelligent AI – which top researchers and experts fear could disempower or wipe out humanity. Scientist Max Tegmark describes an optimistic vision for how we can keep AI under control and ensure it’s working for us, not the other way around.

Researchers at the Humboldt University of Berlin, partners of the DAALI project, have demonstrated a surprising effect present in the fluorescent light of a single atom.

An atom is the smallest component of an element. It is made up of protons and neutrons within the nucleus, and electrons circling the nucleus.

A team led by researchers at Baylor College of Medicine is coming closer to delivering on the promise of personalized breast cancer therapy with a strategy to predict the most likely response of a cancer to a specific less toxic treatment regimen.

In this study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, the scientists developed and validated in clinical trials a multiparameter molecular classifier test to predict with a high degree of confidence which patients with HER2-positive (HER2+) breast cancer would be candidates for anti-HER2 therapy alone without the need for chemotherapy. The molecular classifier also accurately identifies patients whose tumors may need chemo or other targeted therapies.

“HER2+ breast cancer, which represents about one of every five breast cancers, expresses high levels of HER2 proteins and is physiologically dependent on the abundance of this protein to grow fast and metastasize or spread to other organs,” said co-corresponding author Dr. Rachel Schiff, professor of medicine and molecular and cellular biology and member of the Lester and Sue Smith Breast Center and the Dan L Duncan Comprehensive Cancer Center at Baylor. “Historically, HER2+ breast cancer was treated only by chemotherapy, but patient outcomes were poor. This changed in the late 1990s when the introduction of anti-HER2 therapy, drugs that block the growth effects of HER2, transformed the treatment of this disease.”